Fate Therapeutics Inc (FATE)

[jondoeuk]

No, but it is listed in the recent 10-Q. So I expect a trial could happen sometime next year. Not only could this lead to an antibody only conditioning regime, but it has a more specific action and shorter duration of effect over an anti-CD52 mAb. I know ALLO is having to add an anti-CD52 mAb with Cy/Flu, and from memory, both host T-cell and neutrophil recovery didn't start until two months later (with a high dose). Also, the median time to having a normal platelet count was increased to over a week as well.